FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a proteolytically active polypeptide which is capable of hydrolysing botulinic neurotoxin A (BoNT/A) to produce double-stranded botulinum neurotoxin A (BoNT/A).
EFFECT: proteolytically active polypeptide comprising an amino acid sequence having at least 95 % sequence identity of SEQ ID NO: 1 can be used to produce a biologically active double-stranded BoNT/A.
11 cl, 11 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDES | 2018 |
|
RU2719164C1 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| CONSTRUCTED BOTULINUM NEUROTOXIN | 2017 |
|
RU2789302C2 |
| GENETICALLY ENGINEERED CELLS SENSITIVE TO CLOSTRIDIAL NEUROTOXINS | 2020 |
|
RU2824389C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| BOTULINUM NEUROTOXIN BIOHYBRID | 2019 |
|
RU2816855C2 |
| NEW METHODS OF USING BOTULINUM NEUROTOXIN FOR TREATING TREMOR | 2020 |
|
RU2826569C2 |
| COMPLEX, AGENT AND APPLICATION OF TYPE A BOTULINUM TOXIN CLOSTRIDIUM BOTULINUM | 2020 |
|
RU2783511C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS SPECIFICALLY BINDING TO BOTULINUM NEUROTOXIN TYPE A, AND METHOD OF USING THEM FOR THERAPY OR EMERGENCY PREVENTION OF INTOXICATION CAUSED BY BOTULINUM NEUROTOXIN TYPE A | 2021 |
|
RU2766348C1 |
